MX2017011087A - Derivados de tetrahidropiranil benzamida. - Google Patents

Derivados de tetrahidropiranil benzamida.

Info

Publication number
MX2017011087A
MX2017011087A MX2017011087A MX2017011087A MX2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A
Authority
MX
Mexico
Prior art keywords
tetrahydropyranyl
benzamide derivatives
compounds
benzamide
derivatives
Prior art date
Application number
MX2017011087A
Other languages
English (en)
Inventor
Ma Tianwei
Long Hu Zhi
Zhu LIU Lian
Zhou Jingye
Zhang Haizhen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017011087A publication Critical patent/MX2017011087A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la fórmula (1), en donde R, R1-R3 son como se describen en la presente; métodos para tratar pacientes por diabetes usando los compuestos y procesos para preparar los compuestos. (ver Fórmula).
MX2017011087A 2015-03-03 2016-02-19 Derivados de tetrahidropiranil benzamida. MX2017011087A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/073563 WO2016138631A1 (en) 2015-03-03 2015-03-03 Imidazo benzamide compounds
PCT/CN2016/074083 WO2016138821A1 (en) 2015-03-03 2016-02-19 Tetrahydropyranyl benzamide derivatives

Publications (1)

Publication Number Publication Date
MX2017011087A true MX2017011087A (es) 2017-11-10

Family

ID=56849060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011087A MX2017011087A (es) 2015-03-03 2016-02-19 Derivados de tetrahidropiranil benzamida.

Country Status (24)

Country Link
US (1) US10196385B2 (es)
EP (1) EP3265460A4 (es)
JP (1) JP2018507232A (es)
KR (1) KR20170106483A (es)
CN (1) CN107406436B (es)
AU (1) AU2016228055B2 (es)
BR (1) BR112017015448A2 (es)
CA (1) CA2975413A1 (es)
CL (1) CL2017002148A1 (es)
CO (1) CO2017008721A2 (es)
CR (1) CR20170354A (es)
DO (1) DOP2017000196A (es)
EA (1) EA201791745A1 (es)
EC (1) ECSP17058071A (es)
IL (1) IL253405A0 (es)
MA (1) MA41641A (es)
MX (1) MX2017011087A (es)
PE (1) PE20171650A1 (es)
PH (1) PH12017501560A1 (es)
SG (1) SG11201706718RA (es)
SV (1) SV2017005520A (es)
TN (1) TN2017000372A1 (es)
WO (2) WO2016138631A1 (es)
ZA (1) ZA201704948B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014337A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
CN111902413B (zh) 2018-03-09 2023-10-17 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505957A (ja) 2006-10-10 2010-02-25 アムゲン インコーポレイティッド 糖尿病に対して使用されるｎ−アリールピラゾール化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP5685181B2 (ja) * 2009-03-05 2015-03-18 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体
EP2523558A4 (en) * 2010-01-15 2013-06-19 Merck Sharp & Dohme BETA-CARBOLINE OXADIAZOLE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound

Also Published As

Publication number Publication date
PH12017501560A1 (en) 2018-02-05
CO2017008721A2 (es) 2018-01-05
AU2016228055B2 (en) 2018-06-07
KR20170106483A (ko) 2017-09-20
TN2017000372A1 (en) 2019-01-16
CN107406436A (zh) 2017-11-28
PE20171650A1 (es) 2017-11-13
IL253405A0 (en) 2017-09-28
EP3265460A1 (en) 2018-01-10
US20180194755A1 (en) 2018-07-12
EP3265460A4 (en) 2018-08-08
JP2018507232A (ja) 2018-03-15
DOP2017000196A (es) 2017-09-15
CA2975413A1 (en) 2016-09-09
CR20170354A (es) 2017-09-05
WO2016138631A1 (en) 2016-09-09
ECSP17058071A (es) 2017-10-31
SV2017005520A (es) 2018-08-27
SG11201706718RA (en) 2017-09-28
ZA201704948B (en) 2019-02-27
US10196385B2 (en) 2019-02-05
BR112017015448A2 (pt) 2018-01-30
EA201791745A1 (ru) 2018-01-31
CL2017002148A1 (es) 2018-04-13
AU2016228055A1 (en) 2017-08-17
WO2016138821A1 (en) 2016-09-09
MA41641A (fr) 2018-01-09
CN107406436B (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MY181959A (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
NZ761519A (en) Nlrp3 modulators
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
PH12016501613A1 (en) Pyrazines modulators of gpr6
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2016011630A (es) Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.